查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1908571

生物製药市场规模、份额和趋势分析报告：按分子、疾病、药物类型、研发阶段、给药途径、製剂类型、销售管道、地区和细分市场预测（2026-2033 年）

Biopharmaceutical Market Size, Share & Trends Analysis Report By Molecule, By Disease, By Drug Type, By Drug Development Type, By Route Of Administration, By Prescription Type, By Sales Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 255 Pages | 商品交期: 2-10个工作天内

价格

生物製药市场概览

全球生物製药市场预计在 2025 年达到 4.8438 亿美元，预计到 2033 年将达到 8.163 亿美元。

预计从 2026 年到 2033 年，生物製药产业将以 6.55% 的复合年增长率成长。推动生物製药产业成长的因素包括：对标靶治疗的需求不断增长、生物技术的进步、慢性病盛行率的上升以及人口老化。

生物製药产业正经历快速成长，这主要得益于生物技术和药物研发的显着进步。疫苗技术、单株抗体、基因疗法和新一代生物製药的创新正在改变多个治疗领域的治疗模式。这些突破性进展提高了治疗效果，改善了患者预后，并满足了尚未满足的医疗需求。近期发展凸显了这些进步对全球医疗保健格局的影响，并强调了生物製药在疾病控制中的关键作用。

2025年2月，Zydus Lifesciences公司推出印度首款四价流感疫苗VaxiFlu-4，标誌着疫苗技术领域的一项重大突破。这款新型流感疫苗由该公司位于艾哈默德巴德的疫苗技术中心研发，其配方基于世界卫生组织推荐的对抗新出现的流感病毒株的方案。 VaxiFlu-4现已核准中央药学实验室的批准，预计将在预防流感大流行和应对公共卫生挑战方面发挥关键作用。这项创新充分展现了疫苗研发的进步如何加强疾病预防策略，并促进生物製药产业的成长。

目录

第一章调查方法和范围

第二章执行摘要

第三章 生物製药市场变数、趋势与范围

  • 市场趋势展望
  • 市场动态
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 定价分析

第四章 生物製药市场：以分子分類的业务分析

  • 按分子分類的市场份额（2025 年和 2033 年）
  • 按分子分類的市场规模、预测和趋势分析（2021-2033）
  • 单株抗体
  • 干扰素
  • 胰岛素
  • 生长因子和凝血因子
  • 促红血球生成素
  • 疫苗
  • 荷尔蒙
  • 其他的

第五章：生物製药市场：疾病特异性商业分析

  • 按疾病分類的市场份额（2025 年和 2033 年）
  • 按疾病分類的市场规模、预测和趋势分析（2021-2033 年）
  • 肿瘤学
  • 血液疾病
  • 代谢紊乱
  • 感染疾病
  • 心血管疾病
  • 神经系统疾病
  • 免疫学
  • 其他的

第六章：生物製药市场：按药物类型分類的业务分析

  • 按药物类型分類的市场份额（2025 年和 2033 年）
  • 按药物类型分類的市场规模、预测和趋势分析（2021-2033 年）
  • 原创产品（品牌产品）

第七章：生物製药市场：依研发阶段类型分類的商业分析

  • 按发展阶段类型分類的市场份额（2025 年和 2033 年）
  • 按发展阶段类型分類的市场规模、预测和趋势分析（2021-2033 年）
  • 外包
  • 内部开发

第八章：生物製药市场：依製剂类型进行业务分析

  • 按配方分類的市场份额（2025 年和 2033 年）
  • 按配方分類的市场规模、预测和趋势分析（2021-2033 年）
  • 注射（静脉注射、肌肉注射、皮下注射）
  • 吸入剂/滴鼻剂
  • 其他准备工作

第九章 生物製药市场：按给药途径分類的业务分析

  • 按给药途径分類的市场份额（2025 年和 2033 年）
  • 按给药途径分類的市场规模、预测和趋势分析（2021-2033 年）
  • 肠外途径（静脉注射、肌肉注射、皮下注射）
  • 吸入/鼻腔给药
  • 其他的

第十章 生物製药市场：依製剂类型分類的业务分析

  • 按处方类型分類的市场份额（2025 年和 2033 年）
  • 按处方类型分類的市场规模、预测和趋势分析（2021-2033 年）
  • 处方药
  • 非处方药

第十一章 生物製药市场：按销售管道分類的业务分析

  • 按销售管道分類的市场份额（2025 年和 2033 年）
  • 按销售管道分類的市场规模、预测与趋势分析，2021-2033年
  • 零售
  • 非零售

第十二章 生物製药市场：区域、预测与趋势分析

  • 2025年及2033年区域市占率分析
  • 区域市场概览
  • 市场规模、预测与趋势分析（2021-2033）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第十三章 竞争格局

  • 参与公司概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/列表
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • AbbVie Inc.
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • Sanofi
    • GSK plc.
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited
    • Biogen
    • Eli Lilly and Company
    • Novo Nordisk A/S
    • Amgen Inc.
Product Code: GVR-4-68040-534-1

Biopharmaceutical Market Summary

The global biopharmaceutical market size was estimated at USD 484.38 million in 2025 and is projected to reach USD 816.30 million by 2033, growing at a CAGR of 6.55% from 2026 to 2033. The biopharmaceutical industry's growth is driven by increasing demand for targeted therapies, advancements in biotechnology, the rising prevalence of chronic diseases, and an aging population.

The biopharmaceutical industry is witnessing rapid growth, driven by significant advancements in biotechnology and drug development. Innovations in vaccine technology, monoclonal antibodies, gene therapies, and next-generation biologics are transforming treatment paradigms across multiple therapeutic areas. These breakthroughs enhance treatment efficacy, improve patient outcomes, and address unmet medical needs. Recent developments highlight the impact of these advancements on the global healthcare landscape, underscoring the pivotal role of biopharmaceuticals in combating diseases.

In February 2025, Zydus Lifesciences introduced VaxiFlu-4, India's first quadrivalent influenza vaccine, marking a significant leap in vaccine technology. This novel flu protection vaccine, developed at Zydus's Vaccine Technology Centre in Ahmedabad, has been formulated according to the WHO recommended composition to combat emerging strains of the influenza virus. With clearance from the Central Drug Laboratory, VaxiFlu-4 is expected to play a crucial role in preventing flu outbreaks and addressing public health challenges. This innovation exemplifies how advancements in vaccine development are bolstering disease prevention strategies and contributing to the growth of the biopharmaceutical industry.

Global Biopharmaceutical Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biopharmaceutical market report based on molecule type, disease, drug type, drug development type, formulation, route of administration, prescription type, sales channel, and region:

  • Molecule Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Monoclonal Antibody
  • Interferon
  • Insulin
  • Growth and Coagulation Factor
  • Erythropoietin
  • Vaccine
  • Hormone
  • Others
  • Disease Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Blood Disorder
  • Metabolic Disease
  • Infectious Disease
  • Cardiovascular Disease
  • Neurological Disease
  • Immunology
  • Other Applications
  • Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Proprietary (Branded)
  • Biosimilars
  • Drug Development Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Outsource
  • In-house
  • Formulation Outlook (Revenue, USD Million, 2021 - 2033)
  • Injectables (IV, IM, SC)
  • Inhalation/Nasal Sprays
  • Other Formulations
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Parenteral (IV, IM, SC)
  • Inhalation/Nasal
  • Other Routes
  • Prescription Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Prescription Medicines
  • Over-the-counter (OTC) Medicines
  • Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Retail Pharmacies
  • Non-retail
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Molecule Type
    • 1.2.2. Disease
    • 1.2.3. Drug Type
    • 1.2.4. Drug Development Type
    • 1.2.5. Formulation
    • 1.2.6. Route of Administration
    • 1.2.7. Prescription Type
    • 1.2.8. Sales Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Biopharmaceutical Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Pricing Analysis

Chapter 4. Biopharmaceutical Market: Molecule Type Business Analysis

  • 4.1. Molecule Type Market Share, 2025 & 2033
  • 4.2. Molecule Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Molecule Type, 2021 to 2033 (USD Million)
  • 4.4. Monoclonal Antibody
    • 4.4.1. Monoclonal Antibody Market, 2021 - 2033 (USD Million)
  • 4.5. Interferon
    • 4.5.1. Interferon Market, 2021 - 2033 (USD Million)
  • 4.6. Insulin
    • 4.6.1. Insulin Market, 2021 - 2033 (USD Million)
  • 4.7. Growth and Coagulation Factor
    • 4.7.1. Growth and Coagulation Factor Market, 2021 - 2033 (USD Million)
  • 4.8. Erythropoietin
    • 4.8.1. Erythropoietin Market, 2021 - 2033 (USD Million)
  • 4.9. Vaccine
    • 4.9.1. Vaccine Market, 2021 - 2033 (USD Million)
  • 4.10. Hormone
    • 4.10.1. Hormone Market, 2021 - 2033 (USD Million)
  • 4.11. Others
    • 4.11.1. Other Type Market, 2021 - 2033 (USD Million)

Chapter 5. Biopharmaceutical Market: Disease Business Analysis

  • 5.1. Disease Market Share, 2025 & 2033
  • 5.2. Disease Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Million)
  • 5.4. Oncology
    • 5.4.1. Oncology Market, 2021 - 2033 (USD Million)
  • 5.5. Blood Disorder
    • 5.5.1. Blood Disorder Market, 2021 - 2033 (USD Million)
  • 5.6. Metabolic Disease
    • 5.6.1. Metabolic Disease Market, 2021 - 2033 (USD Million)
  • 5.7. Infectious Disease
    • 5.7.1. Infectious Disease Market, 2021 - 2033 (USD Million)
  • 5.8. Cardiovascular Disease
    • 5.8.1. Cardiovascular Disease Market, 2021 - 2033 (USD Million)
  • 5.9. Neurological Disease
    • 5.9.1. Neurological Disease Market, 2021 - 2033 (USD Million)
  • 5.10. Immunology
    • 5.10.1. Immunology Market, 2021 - 2033 (USD Million)
  • 5.11. Others
    • 5.11.1. Other Type Market, 2021 - 2033 (USD Million)

Chapter 6. Biopharmaceutical Market: Drug Type Business Analysis

  • 6.1. Drug Type Market Share, 2025 & 2033
  • 6.2. Drug Type Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
  • 6.4. Proprietary (Branded)
    • 6.4.1. Proprietary (Branded) Market, 2021 - 2033 (USD Million)
    • 6.4.2. Biosimilars
      • 6.4.2.1. Biosimilars Market, 2021 - 2033 (USD Million)

Chapter 7. Biopharmaceutical Market: Drug Development Type Business Analysis

  • 7.1. Drug Development Type Market Share, 2025 & 2033
  • 7.2. Drug Development Type Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Drug Development Type, 2021 to 2033 (USD Million)
  • 7.4. Outsource
    • 7.4.1. Outsource Market, 2021 - 2033 (USD Million)
  • 7.5. In-house
    • 7.5.1. In-house Market, 2021 - 2033 (USD Million)

Chapter 8. Biopharmaceutical Market: Formulation Business Analysis

  • 8.1. Formulation Market Share, 2025 & 2033
  • 8.2. Formulation Segment Dashboard
  • 8.3. Market Size & Forecasts and Trend Analysis, by Formulation, 2021 to 2033 (USD Million)
  • 8.4. Injectables (IV, IM, SC)
    • 8.4.1. Injectables (IV, IM, SC) Market, 2021 - 2033 (USD Million)
  • 8.5. Inhalation/Nasal Sprays
    • 8.5.1. Inhalation/Nasal Sprays Market, 2021 - 2033 (USD Million)
  • 8.6. Other Formulations
    • 8.6.1. Other Formulations Market, 2021 - 2033 (USD Million)

Chapter 9. Biopharmaceutical Market: Route of Administration Business Analysis

  • 9.1. Route of Administration Market Share, 2025 & 2033
  • 9.2. Route of Administration Segment Dashboard
  • 9.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
  • 9.4. Parenteral (IV, IM, SC)
    • 9.4.1. Parenteral (IV, IM, SC) Market, 2021 - 2033 (USD Million)
  • 9.5. Inhalation/Nasal
    • 9.5.1. Inhalation/Nasal Market, 2021 - 2033 (USD Million)
  • 9.6. Other Routes
    • 9.6.1. Other Routes Market, 2021 - 2033 (USD Million)

Chapter 10. Biopharmaceutical Market: Prescription Type Business Analysis

  • 10.1. Prescription Type Market Share, 2025 & 2033
  • 10.2. Prescription Type Segment Dashboard
  • 10.3. Market Size & Forecasts and Trend Analysis, by Prescription Type, 2021 to 2033 (USD Million)
  • 10.4. Prescription Medicines
    • 10.4.1. Prescription Medicines Market, 2021 - 2033 (USD Million)
  • 10.5. Over-the-counter (OTC) Medicines
    • 10.5.1. Over-the-counter (OTC) Medicines Market, 2021 - 2033 (USD Million)

Chapter 11. Biopharmaceutical Market: Sales Channel Business Analysis

  • 11.1. Sales Channel Market Share, 2025 & 2033
  • 11.2. Sales Channel Segment Dashboard
  • 11.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2021 to 2033 (USD Million)
  • 11.4. Retail Pharmacies
    • 11.4.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 11.5. Non-retail
    • 11.5.1. Non-retail Market, 2021 - 2033 (USD Million)

Chapter 12. Biopharmaceutical Market: Regional Estimates & Trend Analysis

  • 12.1. Regional Market Share Analysis, 2025 & 2033
  • 12.2. Regional Market Dashboard
  • 12.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 12.4. North America
    • 12.4.1. North America Biopharmaceutical Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
    • 12.4.2. U.S.
      • 12.4.2.1. Key Country Dynamics
      • 12.4.2.2. Target Disease Prevalence
      • 12.4.2.3. Regulatory Framework
      • 12.4.2.4. Reimbursement Framework
      • 12.4.2.5. U.S. Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.4.3. Canada
      • 12.4.3.1. Key Country Dynamics
      • 12.4.3.2. Target Disease Prevalence
      • 12.4.3.3. Regulatory Framework
      • 12.4.3.4. Reimbursement Framework
      • 12.4.3.5. U.S. Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.4.4. Mexico
      • 12.4.4.1. Key Country Dynamics
      • 12.4.4.2. Target Disease Prevalence
      • 12.4.4.3. Regulatory Framework
      • 12.4.4.4. Reimbursement Framework
      • 12.4.4.5. Mexico Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.5. Europe
    • 12.5.1. Europe Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.5.2. UK
      • 12.5.2.1. Key Country Dynamics
      • 12.5.2.2. Target Disease Prevalence
      • 12.5.2.3. Regulatory Framework
      • 12.5.2.4. Reimbursement Framework
      • 12.5.2.5. Uk Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.5.3. Germany
      • 12.5.3.1. Key Country Dynamics
      • 12.5.3.2. Target Disease Prevalence
      • 12.5.3.3. Regulatory Framework
      • 12.5.3.4. Reimbursement Framework
      • 12.5.3.5. Germany Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.5.4. France
      • 12.5.4.1. Key Country Dynamics
      • 12.5.4.2. Target Disease Prevalence
      • 12.5.4.3. Regulatory Framework
      • 12.5.4.4. Reimbursement Framework
      • 12.5.4.5. France Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.5.5. Italy
      • 12.5.5.1. Key Country Dynamics
      • 12.5.5.2. Target Disease Prevalence
      • 12.5.5.3. Regulatory Framework
      • 12.5.5.4. Reimbursement Framework
      • 12.5.5.5. Italy Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.5.6. Spain
      • 12.5.6.1. Key Country Dynamics
      • 12.5.6.2. Target Disease Prevalence
      • 12.5.6.3. Regulatory Framework
      • 12.5.6.4. Reimbursement Framework
      • 12.5.6.5. Spain Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.5.7. Denmark
      • 12.5.7.1. Key Country Dynamics
      • 12.5.7.2. Target Disease Prevalence
      • 12.5.7.3. Regulatory Framework
      • 12.5.7.4. Reimbursement Framework
      • 12.5.7.5. Denmark Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.5.8. Sweden
      • 12.5.8.1. Key Country Dynamics
      • 12.5.8.2. Target Disease Prevalence
      • 12.5.8.3. Regulatory Framework
      • 12.5.8.4. Reimbursement Framework
      • 12.5.8.5. Sweden Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.5.9. Norway
      • 12.5.9.1. Key Country Dynamics
      • 12.5.9.2. Target Disease Prevalence
      • 12.5.9.3. Regulatory Framework
      • 12.5.9.4. Reimbursement Framework
      • 12.5.9.5. Norway Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.6. Asia Pacific
    • 12.6.1. Asia Pacific Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.6.2. Japan
      • 12.6.2.1. Key Country Dynamics
      • 12.6.2.2. Target Disease Prevalence
      • 12.6.2.3. Regulatory Framework
      • 12.6.2.4. Reimbursement Framework
      • 12.6.2.5. Japan Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.6.3. China
      • 12.6.3.1. Key Country Dynamics
      • 12.6.3.2. Target Disease Prevalence
      • 12.6.3.3. Regulatory Framework
      • 12.6.3.4. Reimbursement Framework
      • 12.6.3.5. China Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.6.4. India
      • 12.6.4.1. Key Country Dynamics
      • 12.6.4.2. Target Disease Prevalence
      • 12.6.4.3. Regulatory Framework
      • 12.6.4.4. Reimbursement Framework
      • 12.6.4.5. India Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.6.5. Australia
      • 12.6.5.1. Key Country Dynamics
      • 12.6.5.2. Target Disease Prevalence
      • 12.6.5.3. Regulatory Framework
      • 12.6.5.4. Reimbursement Framework
      • 12.6.5.5. Australia Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.6.6. South Korea
      • 12.6.6.1. Key Country Dynamics
      • 12.6.6.2. Target Disease Prevalence
      • 12.6.6.3. Regulatory Framework
      • 12.6.6.4. Reimbursement Framework
      • 12.6.6.5. South Korea Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.6.7. Thailand
      • 12.6.7.1. Key Country Dynamics
      • 12.6.7.2. Target Disease Prevalence
      • 12.6.7.3. Regulatory Framework
      • 12.6.7.4. Reimbursement Framework
      • 12.6.7.5. Thailand Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.7. Latin America
    • 12.7.1. Latin America Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.7.2. Brazil
      • 12.7.2.1. Key Country Dynamics
      • 12.7.2.2. Target Disease Prevalence
      • 12.7.2.3. Regulatory Framework
      • 12.7.2.4. Reimbursement Framework
      • 12.7.2.5. Japan Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.7.3. Argentina
      • 12.7.3.1. Key Country Dynamics
      • 12.7.3.2. Target Disease Prevalence
      • 12.7.3.3. Regulatory Framework
      • 12.7.3.4. Reimbursement Framework
      • 12.7.3.5. China Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.8. Middle East and Africa
    • 12.8.1. Middle East and Africa Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.8.2. South Africa
      • 12.8.2.1. Key Country Dynamics
      • 12.8.2.2. Target Disease Prevalence
      • 12.8.2.3. Regulatory Framework
      • 12.8.2.4. Reimbursement Framework
      • 12.8.2.5. South Africa Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.8.3. Saudi Arabia
      • 12.8.3.1. Key Country Dynamics
      • 12.8.3.2. Target Disease Prevalence
      • 12.8.3.3. Regulatory Framework
      • 12.8.3.4. Reimbursement Framework
      • 12.8.3.5. Saudi Arabia Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.8.4. UAE
      • 12.8.4.1. Key Country Dynamics
      • 12.8.4.2. Target Disease Prevalence
      • 12.8.4.3. Regulatory Framework
      • 12.8.4.4. Reimbursement Framework
      • 12.8.4.5. UAE Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 12.8.5. Kuwait
      • 12.8.5.1. Key Country Dynamics
      • 12.8.5.2. Target Disease Prevalence
      • 12.8.5.3. Regulatory Framework
      • 12.8.5.4. Reimbursement Framework
      • 12.8.5.5. Kuwait Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 13. Competitive Landscape

  • 13.1. Participant Overview
  • 13.2. Company Market Position Analysis
  • 13.3. Company Categorization
  • 13.4. Strategy Mapping
  • 13.5. Company Profiles/Listing
    • 13.5.1. F. Hoffmann-La Roche Ltd
      • 13.5.1.1. Overview
      • 13.5.1.2. Financial Performance
      • 13.5.1.3. Product Benchmarking
      • 13.5.1.4. Strategic Initiatives
    • 13.5.2. Novartis AG
      • 13.5.2.1. Overview
      • 13.5.2.2. Financial Performance
      • 13.5.2.3. Product Benchmarking
      • 13.5.2.4. Strategic Initiatives
    • 13.5.3. AbbVie Inc.
      • 13.5.3.1. Overview
      • 13.5.3.2. Financial Performance
      • 13.5.3.3. Product Benchmarking
      • 13.5.3.4. Strategic Initiatives
    • 13.5.4. Johnson & Johnson Services, Inc.
      • 13.5.4.1. Overview
      • 13.5.4.2. Financial Performance
      • 13.5.4.3. Product Benchmarking
      • 13.5.4.4. Strategic Initiatives
    • 13.5.5. Merck & Co., Inc.
      • 13.5.5.1. Overview
      • 13.5.5.2. Financial Performance
      • 13.5.5.3. Product Benchmarking
      • 13.5.5.4. Strategic Initiatives
    • 13.5.6. Pfizer Inc.
      • 13.5.6.1. Overview
      • 13.5.6.2. Financial Performance
      • 13.5.6.3. Product Benchmarking
      • 13.5.6.4. Strategic Initiatives
    • 13.5.7. Bristol-Myers Squibb Company
      • 13.5.7.1. Overview
      • 13.5.7.2. Financial Performance
      • 13.5.7.3. Product Benchmarking
      • 13.5.7.4. Strategic Initiatives
    • 13.5.8. Sanofi
      • 13.5.8.1. Overview
      • 13.5.8.2. Financial Performance
      • 13.5.8.3. Product Benchmarking
      • 13.5.8.4. Strategic Initiatives
    • 13.5.9. GSK plc.
      • 13.5.9.1. Overview
      • 13.5.9.2. Financial Performance
      • 13.5.9.3. Product Benchmarking
      • 13.5.9.4. Strategic Initiatives
    • 13.5.10. AstraZeneca
      • 13.5.10.1. Overview
      • 13.5.10.2. Financial Performance
      • 13.5.10.3. Product Benchmarking
      • 13.5.10.4. Strategic Initiatives
    • 13.5.11. Takeda Pharmaceutical Company Limited
      • 13.5.11.1. Overview
      • 13.5.11.2. Financial Performance
      • 13.5.11.3. Product Benchmarking
      • 13.5.11.4. Strategic Initiatives
    • 13.5.12. Biogen
      • 13.5.12.1. Overview
      • 13.5.12.2. Financial Performance
      • 13.5.12.3. Product Benchmarking
      • 13.5.12.4. Strategic Initiatives
    • 13.5.13. Eli Lilly and Company
      • 13.5.13.1. Overview
      • 13.5.13.2. Financial Performance
      • 13.5.13.3. Product Benchmarking
      • 13.5.13.4. Strategic Initiatives
    • 13.5.14. Novo Nordisk A/S
      • 13.5.14.1. Overview
      • 13.5.14.2. Financial Performance
      • 13.5.14.3. Product Benchmarking
      • 13.5.14.4. Strategic Initiatives
    • 13.5.15. Amgen Inc.
      • 13.5.15.1. Overview
      • 13.5.15.2. Financial Performance
      • 13.5.15.3. Product Benchmarking
      • 13.5.15.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Biopharmaceutical Market, by Region, 2021 - 2033 (USD Million)
  • Table 4 Global Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 5 Global Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 6 Global Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 7 Global Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 8 Global Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 9 Global Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 10 Global Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 11 Global Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 12 North America Biopharmaceutical Market, by Country, 2021 - 2033 (USD Million)
  • Table 13 North America Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 14 North America Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 15 North America Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 16 North America Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 17 North America Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 18 North America Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 19 North America Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 20 North America Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 21 U.S Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 22 U.S Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 23 U.S Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 24 U S Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 25 U.S Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 26 U.S Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 27 U.S Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 28 U.S Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 29 Canada Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 30 Canada Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 31 Canada Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 32 Canada Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 33 Canada Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 34 Canada Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 35 Canada Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 36 Canada Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 37 Mexico Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 38 Mexico Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 39 Table 39 Mexico Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 40 Mexico Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 41 Mexico Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 42 Mexico Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 43 Mexico Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 44 Mexico Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 45 Europe Biopharmaceutical Market, by Country, 2021 - 2033 (USD Million)
  • Table 46 Europe Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 47 Europe Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 48 Europe Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 49 Europe Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 50 Europe Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 51 Europe Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 52 Europe Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 53 Europe Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 54 UK Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 55 UK Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 56 UK Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 57 UK Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 58 UK Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 59 UK Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 60 UK Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 61 UK Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 62 Germany Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 63 Germany Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 64 Germany Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 65 Germany Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 66 Germany Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 67 Germany Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 68 Germany Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 69 Germany Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 70 France Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 71 France Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 72 France Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 73 France Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 74 France Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 75 France Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 76 France Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 77 France Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 78 Italy Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 79 Italy Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 80 Italy Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 81 Italy Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 82 Italy Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 83 Italy Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 84 Italy Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 85 Italy Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 86 Spain Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 87 Spain Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 88 Spain Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 89 Spain Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 90 Spain Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 91 Spain Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 92 Spain Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 93 Spain Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 94 Norway Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 95 Norway Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 96 Table 96 Norway Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 97 Norway Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 98 Norway Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 99 Norway Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 100 Norway Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 101 Norway Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 102 Denmark Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 103 Denmark Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 104 Denmark Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 105 Denmark Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 106 Denmark Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 107 Denmark Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 108 Denmark Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 109 Denmark Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 110 Sweden Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 111 Sweden Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 112 Sweden Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 113 Sweden Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 114 Sweden Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 115 Sweden Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 116 Sweden Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 117 Sweden Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 118 Asia Pacific Biopharmaceutical Market, by Country, 2021 - 2033 (USD Million)
  • Table 119 Asia Pacific Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 120 Asia Pacific Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 121 Asia Pacific Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 122 Asia Pacific Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 123 Asia Pacific Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 124 Asia Pacific Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 125 Asia Pacific Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 126 Asia Pacific Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 127 Japan Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 128 Japan Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 129 Japan Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 130 Japan Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 131 Japan Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 132 Japan Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 133 Japan Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 134 Japan Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 135 Table 135 China Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 136 Table 136 China Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 137 China Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 138 China Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 139 China Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 140 China Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 141 China Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 142 China Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 143 India Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 144 India Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 145 India Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 146 India Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 147 India Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 148 India Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 149 India Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 150 India Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 151 Australia Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 152 Australia Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 153 Australia Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 154 Australia Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 155 Australia Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 156 Australia Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 157 Australia Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 158 Australia Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 159 South Korea Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 160 South Korea Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 161 South Korea Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 162 South Korea Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 163 South Korea Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 164 South Korea Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 165 South Korea Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 166 South Korea Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 167 Thailand Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 168 Thailand Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 169 Thailand Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 170 Thailand Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 171 Thailand Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 172 Thailand Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 173 Thailand Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 174 Thailand Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 175 Latin America Biopharmaceutical Market, by Country, 2021 - 2033 (USD Million)
  • Table 176 Latin America Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 177 Latin America Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 178 Latin America Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 179 Latin America Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 180 Latin America Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 181 Latin America Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 182 Latin America Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 183 Latin America Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 184 Brazil Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 185 Brazil Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 186 Brazil Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 187 Brazil Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 188 Brazil Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 189 Brazil Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 190 Brazil Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 191 Brazil Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 192 Argentina Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 193 Argentina Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 194 Argentina Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 195 Argentina Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 196 Argentina Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 197 Argentina Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 198 Argentina Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 199 Argentina Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 200 Middle East & Africa Biopharmaceutical Market, by Country, 2021 - 2033 (USD Million)
  • Table 201 Middle East & Africa Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 202 Middle East & Africa Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 203 Middle East & Africa Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 204 Middle East & Africa Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 205 Middle East & Africa Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 206 Middle East & Africa Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 207 Middle East & Africa Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 208 Middle East & Africa Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 209 South Africa Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 210 South Africa Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 211 South Africa Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 212 South Africa Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 213 South Africa Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 214 South Africa Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 215 South Africa Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 216 South Africa Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 217 Saudi Arabia Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 218 Saudi Arabia Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 219 Saudi Arabia Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 220 Saudi Arabia Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 221 Saudi Arabia Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 222 Saudi Arabia Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 223 Saudi Arabia Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 224 Saudi Arabia Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 225 UAE Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 226 UAE Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 227 UAE Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 228 UAE Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 229 UAE Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 230 UAE Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 231 UAE Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 232 UAE Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 233 Kuwait Biopharmaceutical Market, by Molecule Type, 2021 - 2033 (USD Million)
  • Table 234 Kuwait Biopharmaceutical Market, by Disease, 2021 - 2033 (USD Million)
  • Table 235 Kuwait Biopharmaceutical Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 236 Kuwait Biopharmaceutical Market, by Drug Development Type, 2021 - 2033 (USD Million)
  • Table 237 Kuwait Biopharmaceutical Market, by Formulation, 2021 - 2033 (USD Million)
  • Table 238 Kuwait Biopharmaceutical Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 239 Kuwait Biopharmaceutical Market, by Prescription Type, 2021 - 2033 (USD Million)
  • Table 240 Kuwait Biopharmaceutical Market, by Sales Channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Biopharmaceutical market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Segment snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Parent market value, 2025 (USD million)
  • Fig. 16 Market dynamics
  • Fig. 17 Global large pharma R&D spending in USD million, 2018-2023
  • Fig. 18 Porter's five forces analysis
  • Fig. 19 PESTLE analysis
  • Fig. 20 Biopharmaceutical market: Molecule type outlook and key takeaways
  • Fig. 21 Biopharmaceutical market: Molecule type movement analysis
  • Fig. 22 Monoclonal antibody market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Interferon market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 Insulin market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Growth and coagulation factor market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Erythropoietin market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Vaccines market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 Hormone market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 30 Biopharmaceutical market: Disease outlook and key takeaways
  • Fig. 31 Biopharmaceutical market: Disease movement analysis
  • Fig. 32 Oncology market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 33 Blood disorder market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 Metabolic disease market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 35 Infectious disease market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 36 Cardiovascular disease market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 37 Neurological disease market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 38 Immunology market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 39 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 40 Biopharmaceutical market: Drug Type outlook and key takeaways
  • Fig. 41 Biopharmaceutical market: Drug type movement analysis
  • Fig. 42 Proprietary (Branded) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 43 Biosimilars market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 44 Biopharmaceutical market: Drug development type outlook and key takeaways
  • Fig. 45 Biopharmaceutical market: Drug development type movement analysis
  • Fig. 46 Outsource market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 47 In-house market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 48 Biopharmaceutical market: Formulation outlook and key takeaways
  • Fig. 49 Biopharmaceutical market: Formulation movement analysis
  • Fig. 50 Injectable market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 51 Inhalation/nasal sprays market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 52 Other formulations market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 53 Biopharmaceutical market: Prescription outlook and key takeaways
  • Fig. 54 Biopharmaceutical market: Prescription movement analysis
  • Fig. 55 Prescription medicines market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 56 OTC market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 57 Biopharmaceuticals market: Route of administration outlook and key takeaways
  • Fig. 58 Biopharmaceuticals market: Route of administration movement analysis
  • Fig. 59 Parenteral market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 60 Inhalations/Nasal market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 61 Other routes of administration market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 62 Biopharmaceuticals market Sales channel market outlook and key takeaways
  • Fig. 63 Biopharmaceuticals market Sales channel market movement analysis
  • Fig. 64 Retail market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 65 Non-retail market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 66 Biopharmaceutical market revenue, by region, 2025 & 2033 USD million
  • Fig. 67 Regional marketplace: Key takeaways
  • Fig. 68 North America biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 U S biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Cancer incidence, 2022-2045
  • Fig. 72 U S healthcare system: money flow
  • Fig. 73 Key country dynamics
  • Fig. 74 Canada biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Cancer incidence, 2022-2045
  • Fig. 76 Key country dynamics
  • Fig. 77 Mexico biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Cancer incidence, 2022-2045
  • Fig. 79 Regulatory framework
  • Fig. 80 Europe biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 Obesity and diabetes in European nations
  • Fig. 82 Causes of mortality in Europe
  • Fig. 83 Key country dynamics
  • Fig. 84 UK biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 Cancer incidence, 2022-2045
  • Fig. 86 Key country dynamics
  • Fig. 87 Germany biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Cancer incidence, 2022-2045
  • Fig. 89 R&D spending
  • Fig. 90 Exclusivity formula
  • Fig. 91 Germany insurance coverage
  • Fig. 92 Key country dynamics
  • Fig. 93 France biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 Cancer incidence, 2022-2045
  • Fig. 95 Key country dynamics
  • Fig. 96 Italy biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 97 Cancer incidence, 2022-2045
  • Fig. 98 Key country dynamics
  • Fig. 99 Spain biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 100 Cancer incidence, 2022-2045
  • Fig. 101 Key country dynamics
  • Fig. 102 Denmark biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 103 Cancer Incidence, 2022-2045
  • Fig. 104 Key country dynamics
  • Fig. 105 Sweden biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 106 Cancer incidence 2022-2045
  • Fig. 107 Key country dynamics
  • Fig. 108 Norway biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 109 Cancer incidence, 2022-2045
  • Fig. 110 Rest of Europe biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 111 Asia Pacific biopharmaceutical market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 112 Key country dynamics
  • Fig. 113 Japan biopharmaceutical market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 114 Cancer incidence, 2022-2045
  • Fig. 115 Japan pharmaceutical registration
  • Fig. 116 Key country dynamics
  • Fig. 117 China biopharmaceutical market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 118 Cancer incidence, 2022-2045
  • Fig. 119 Regulatory details: China
  • Fig. 120 Key country dynamics
  • Fig. 121 India biopharmaceutical market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 122 Cancer incidence, 2021 - 2033
  • Fig. 123 Key country dynamics
  • Fig. 124 Australia biopharmaceutical market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 125 Cancer incidence, 2021 - 2033
  • Fig. 126 Key country dynamics
  • Fig. 127 Thailand biopharmaceutical market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 128 Cancer incidence, 2021 - 2033
  • Fig. 129 Key country dynamics
  • Fig. 130 South Korea biopharmaceutical market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 131 Cancer incidence, 2021 - 2033
  • Fig. 132 Rest of Asia Pacific biopharmaceutical market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 133 Latin America biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 134 Key country dynamics
  • Fig. 135 Brazil biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 136 Cancer incidence, 2021 - 2033
  • Fig. 137 Key country dynamics
  • Fig. 138 Argentina biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 139 Cancer incidence, 2021 - 2033
  • Fig. 140 Rest of Latin America biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 141 MEA biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 142 Key country dynamics
  • Fig. 143 South Africa biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 144 ancer incidence, 2021 - 2033
  • Fig. 145 Key country dynamics
  • Fig. 146 Saudi Arabia biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 147 Cancer incidence, 2021 - 2033
  • Fig. 148 Key country dynamics
  • Fig. 149 UAE biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 150 Cancer incidence, 2021 - 2033
  • Fig. 151 UAE import and export details
  • Fig. 152 Key country dynamics
  • Fig. 153 Kuwait biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 154 Cancer incidence, 2021 - 2033
  • Fig. 155 Kuwait imports and export details
  • Fig. 156 Rest of MEA biopharmaceutical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 157 Company/competition categorization
  • Fig. 158 Strategy mapping